regulator of G protein signaling 16Genealiases: A28-RGS14 · A28-RGS14P · RGS-R
Q-omics provides the consensus-scored RGS16 profile across patient tissues and cancer cell-line models. RGS16 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, RGS16 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, RGS16 RNA expression shows 15,487 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LGG, COAD, and UVM as cancer lineages where RGS16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RGS16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RGS16 survival associations across molecular data types. RGS16 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RGS16 RNA expression–survival associations across cancer types. High RGS16 expression shows unfavorable associations in LGG, KIRC, ESCA, KIRP, BRCA and COAD. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for RGS16 RNA expression.
This table summarizes RGS16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RGS16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RGS16 shows lower tumor expression in THCA, KIRP and LUAD and higher tumor expression in COAD, STAD and KICH. The COAD box plot shows higher RGS16 RNA expression in tumor versus normal tissue (log2 FC = +2.224, t-test p < 0.001).
This table shows molecular features associated with RGS16 in patient tissues and cancer cell lines. In patient samples, RGS16 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RGS16 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BONE.
